Recursion Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Najat Khan
- Full Time Employees
- 600
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 41 South Rio Grande Street Salt Lake City UT United States of America 84101
- IPO Date
- Apr 16, 2021
- CIK
- 0001601830
- Website
- recursion.com
- Similar Companies
- Business
- Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company specializing in AI-driven drug discovery and development. The company offers an advanced drug discovery platform called the Recursion Operating System (Recursion OS), which integrates machine learning, automation, and large-scale biological and chemical datasets to accelerate the identification and development of novel drug candidates. Its product portfolio includes a pipeline of clinical and preclinical drug candidates targeting oncology and rare diseases, such as REC-617, an oral CDK7 inhibitor for advanced solid tumors, REC-1245, a potential first-in-class RBM39 degrader, REC-4881 for familial adenomatous polyposis, and REC-3964, a potential first-in-class Clostridioides difficile infection toxin B inhibitor. The company also develops biological maps including neuroscience phenomaps and owns proprietary datasets spanning phenomics, transcriptomics, proteomics, and patient data, supported by its automated wet lab platform. Recursion operates globally with key partnerships including Roche/Genentech, Sanofi, Bayer, and Merck KGaA. It was founded in 2013 and is headquartered in Salt Lake City, Utah. Recent major developments include acquiring full rights to the REV102 oral ENPP1 inhibitor program from Rallybio for treating hypophosphatasia, aiming to develop the first oral disease-modifying treatment for the rare genetic disorder. In 2024-2025, Recursion executed a significant business combination with Exscientia, enhancing its platform capabilities by integrating precision chemistry into drug design cycles. The company has streamlined its pipeline by discontinuing or pausing several late-stage drug programs as part of cost reduction and strategic reprioritization, focusing on six active development programs currently mostly in oncology and rare diseases. It secured milestone payments exceeding $500 million cumulatively from partnerships and maintains a strong cash position with a runway into late 2027. Its latest clinical milestones include promising safety and efficacy data from multiple programs and initiation of new clinical trials in solid tumors, lymphoma, and rare diseases, leveraging its AI-powered platform to innovate drug discovery and development processes. Recursion's industry focus lies in biotech and pharmaceutical sectors, targeting patients with aggressive cancers, rare diseases, and other conditions with high unmet medical needs through its proprietary tech-enabled drug discovery system. The company continues to develop its ecosystem of AI and wet lab capabilities to decode complex biology and accelerate the path to novel therapeutic solutions. Its strategic alliances and technology platform position it as a leading clinical-stage biotech entity advancing a data-driven approach to pharmaceutical innovation.
Amova Asset Management Americas Inc. Sells 801,804 Shares of Recursion Pharmaceuticals, Inc. $RXRX
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today
2 Beaten-Down Stocks That Still Aren't Worth Buying
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
Recursion to Participate in Upcoming Investor Conferences